摘要
目的观察甘精胰岛素联合瑞格列奈治疗初诊2型糖尿病的临床疗效。方法选择初诊2型糖尿病患者112例随机分为两组，观察组56例采用甘精胰岛素联合瑞格列奈治疗，对照组采用诺和灵30R进行治疗，比较治疗前后两组空腹血糖（FBG）、餐后2h血糖（2hPG）、糖化血红蛋白（HbAIC）水平变化，及血糖达标时间、胰岛素用量及低血糖发生率情况。结果两组治疗后FPG、2hPG及HbAlc水平均明显降低（均P〈0．05），但两组治疗后FPG、2hPG及HbA1c水平差异无均统计学意义（均P〉0．05）。观察组血糖达标时间、胰岛素用量及低血糖发生率均少于对照组（均P〈0．05）。结论甘精胰岛素联合瑞格列奈治疗初诊2型糖尿病，能有效的控制空腹和饭后血糖，且血糖达标时间短，胰岛素用量少，大大降低了低血糖的发生。
Objective To observe the clinical effects of insulin glargine combined with novonorm in treatment of patients with newly diagnosed type 2 diabetes. Methods 112 cases of wewly diagnosed type 2 diabetes patients were randomly separated into observation group（56 cases）and control group（56 cases）. Observation group was treated with insulin glargine combined with novonorm. Control group was treated with novolin30R. The levels of FPG, 2hPG and HbA1 c before and after treatment, the control time of blood sugar, amounts of insulin and incidence of low blood sugar were observed in both groups. Results Compared with pre-treatment, FPG,2hPG and HbA1 c were significantly decreased （ all P 〈 0.05 ） after treatment, but there were no significant differences in both two groups （ P 〉 0. 05 ）. The control time of blood sugar, amounts of insulin and incidence of low blood sugar in observation group were significantly lower than those in control group （ all P 〈 0. 05 ）. Conclusion Insulin glargine combined with novonorm in treatment of patients with newly diagnosed type 2 diabetes could effectively control blood sugar, shorten the control time of blood sugar, decrease amounts of insulin, and low incidence of low blood sugar.
出处
《中国基层医药》
CAS
2011年第2期177-179,共3页
Chinese Journal of Primary Medicine and Pharmacy
